HIV-gp120 and physical dependence to buprenorphine

• The physical dependence to methadone occurs earlier compared to buprenorphine.
• gp120 did not enhance or precipitate buprenorphine withdrawal.
• Buprenorphine could be the better therapeutic option to manage opioid dependence in HIV patients.

BackgroundOpioids are among the most effective and commonly used analgesics in clinical practice for severe pain. However, the use of opioid medications is clinically limited by several adverse properties including dependence. While opioid dependence is a complex health condition, the treatment of HIV-infected individuals with opioid dependence presents additional challenges. The goal of this study was to examine the physical dependence to buprenorphine in the context of HIV.MethodsYoung adult male rats (Sprague–Dawley) were pretreated with HIV-1 envelope glycoprotein 120 (gp120) injected into the periaqueductal gray area (PAG) and we examined the impact on physical dependence to opioid.ResultsIt was found that the physical dependence to methadone occurred earlier than that to buprenorphine, and that gp120 did not enhance or precipitate the buprenorphine withdrawal.ConclusionThe results suggest that buprenorphine could be the better therapeutic option to manage opioid dependence in HIV.